A review of the main genetic factors influencing the course of COVID-19 in Sardinia: the role of human leukocyte antigen-G

Introduction A large number of risk and protective factors have been identified during the SARS-CoV-2 pandemic which may influence the outcome of COVID-19. Among these, recent studies have explored the role of HLA-G molecules and their immunomodulatory effects in COVID-19, but there are very few reports exploring the genetic basis of these manifestations. The present study aims to investigate how host genetic factors, including HLA-G gene polymorphisms and sHLA-G, can affect SARS-CoV-2 infection. Materials and Methods We compared the immune-genetic and phenotypic characteristics between COVID-19 patients (n = 381) with varying degrees of severity of the disease and 420 healthy controls from Sardinia (Italy). Results HLA-G locus analysis showed that the extended haplotype HLA-G*01:01:01:01/UTR-1 was more prevalent in both COVID-19 patients and controls. In particular, this extended haplotype was more common among patients with mild symptoms than those with severe symptoms [22.7% vs 15.7%, OR = 0.634 (95% CI 0.440 – 0.913); P = 0.016]. Furthermore, the most significant HLA-G 3’UTR polymorphism (rs371194629) shows that the HLA-G 3’UTR Del/Del genotype frequency decreases gradually from 27.6% in paucisymptomatic patients to 15.9% in patients with severe symptoms (X2 = 7.095, P = 0.029), reaching the lowest frequency (7.0%) in ICU patients (X2 = 11.257, P = 0.004). However, no significant differences were observed for the soluble HLA-G levels in patients and controls. Finally, we showed that SARS-CoV-2 infection in the Sardinian population is also influenced by other genetic factors such as β-thalassemia trait (rs11549407C>T in the HBB gene), KIR2DS2/HLA-C C1+ group combination and the HLA-B*58:01, C*07:01, DRB1*03:01 haplotype which exert a protective effect [P = 0.005, P = 0.001 and P = 0.026 respectively]. Conversely, the Neanderthal LZTFL1 gene variant (rs35044562A>G) shows a detrimental consequence on the disease course [P = 0.001]. However, by using a logistic regression model, HLA-G 3’UTR Del/Del genotype was independent from the other significant variables [ORM = 0.4 (95% CI 0.2 – 0.7), PM = 6.5 x 10-4]. Conclusion Our results reveal novel genetic variants which could potentially serve as biomarkers for disease prognosis and treatment, highlighting the importance of considering genetic factors in the management of COVID-19 patients.

[1]  T. Lancet The COVID-19 pandemic in 2023: far from over , 2023, The Lancet.

[2]  B. Chen,et al.  Human genetic basis of severe or critical illness in COVID-19 , 2022, Frontiers in Cellular and Infection Microbiology.

[3]  Yaolong Chen,et al.  Clinical manifestations of COVID‐19: An overview of 102 systematic reviews with evidence mapping , 2022, Journal of evidence-based medicine.

[4]  N. Chitnis,et al.  Modelling the impact of Omicron and emerging variants on SARS-CoV-2 transmission and public health burden , 2022, Communications Medicine.

[5]  Iman A. Mohammed,et al.  Genetic regulation of OAS1 nonsense-mediated decay underlies association with COVID-19 hospitalization in patients of European and African ancestries , 2022, Nature Genetics.

[6]  C. Maldonado-Bernal,et al.  Natural killer cell exhaustion in SARS-CoV-2 infection , 2022, Innate immunity.

[7]  Fei Shao,et al.  BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection , 2022, Nature.

[8]  M. Mohammadnia-Afrouzi,et al.  The association of decreased HLA-G+ immune cell frequencies with critical COVID-19 patients , 2022, Microbial Pathogenesis.

[9]  A. Wilder-Smith,et al.  Does the World Still Need New Covid-19 Vaccines? , 2022, The New England journal of medicine.

[10]  A. Iolascon,et al.  Germline rare variants of lectin pathway genes predispose to asymptomatic SARS-CoV-2 infection in elderly individuals , 2022, Genetics in Medicine.

[11]  A. Perra,et al.  A Protective HLA Extended Haplotype Outweighs the Major COVID-19 Risk Factor Inherited From Neanderthals in the Sardinian Population , 2022, Frontiers in Immunology.

[12]  J. Granados,et al.  Protective HLA alleles against severe COVID-19: HLA-A*68 as an ancestral protection allele in Tapachula-Chiapas, Mexico , 2022, Clinical Immunology.

[13]  Madhavrao D. Chavan,et al.  Current evidence on efficacy of COVID‐19 booster dose vaccination against the Omicron variant: A systematic review , 2022, Journal of medical virology.

[14]  A. Ad’hiah,et al.  HLA-G 14-bp insertion/deletion polymorphism and risk of coronavirus disease 2019 (COVID-19) among Iraqi patients , 2022, Human Immunology.

[15]  H. Zeberg The major genetic risk factor for severe COVID-19 is associated with protection against HIV , 2022, Proceedings of the National Academy of Sciences of the United States of America.

[16]  B. Seliger,et al.  Role of HLA-G in Viral Infections , 2022, Frontiers in Immunology.

[17]  Q. Ye,et al.  The emergence and epidemic characteristics of the highly mutated SARS‐CoV‐2 Omicron variant , 2022, Journal of medical virology.

[18]  Mark S. Anderson,et al.  Human genetic and immunological determinants of critical COVID-19 pneumonia , 2022, Nature.

[19]  Xiao Chen,et al.  Impact of vaccination on the COVID-19 pandemic in U.S. states , 2022, Scientific Reports.

[20]  Wenzhong Liu,et al.  COVID-19: Attacks the 1-beta Chain of Hemoglobin to Disrupt Respiratory Function and Escape Immunity , 2022 .

[21]  Theodore G. Drivas,et al.  Multi-ancestry fine mapping implicates OAS1 splicing in risk of severe COVID-19 , 2022, Nature Genetics.

[22]  D. Singh,et al.  SARS-CoV-2: Emergence of New Variants and Effectiveness of Vaccines , 2021, Frontiers in Cellular and Infection Microbiology.

[23]  A. Lin,et al.  Perspective of HLA-G Induced Immunosuppression in SARS-CoV-2 Infection , 2021, Frontiers in Immunology.

[24]  A. Hajeer,et al.  Association of KIR gene polymorphisms with COVID-19 disease , 2021, Clinical Immunology.

[25]  Marek J. Łos,et al.  An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment , 2021, Drug Resistance Updates.

[26]  A. Bjourson,et al.  Role of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease , 2021, Cells.

[27]  Q. Ye,et al.  The global epidemic of SARS‐CoV‐2 variants and their mutational immune escape , 2021, Journal of medical virology.

[28]  J. Todd,et al.  Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus , 2021, Nature Genetics.

[29]  R. Rizzo,et al.  Increased sHLA-G Is Associated with Improved COVID-19 Outcome and Reduced Neutrophil Adhesion , 2021, Viruses.

[30]  T. Fiolet,et al.  Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review , 2021, Clinical Microbiology and Infection.

[31]  A. Ad’hiah,et al.  Soluble HLA-G is upregulated in serum of patients with severe COVID-19 , 2021, Human Immunology.

[32]  S. Pääbo,et al.  A genomic region associated with protection against severe COVID-19 is inherited from Neandertals , 2021, Proceedings of the National Academy of Sciences.

[33]  Dingtao Hu,et al.  Influence of age and gender on the epidemic of COVID-19 , 2021, Wiener klinische Wochenschrift.

[34]  Q. Lu,et al.  COVID-19 and autoimmune diseases , 2020, Current opinion in rheumatology.

[35]  F. Meloni,et al.  Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience , 2020, Frontiers in Immunology.

[36]  Q. Ye,et al.  Kidney involvement in COVID‐19 and its treatments , 2020, Journal of medical virology.

[37]  P. Kuppen,et al.  The Molecular and Functional Characteristics of HLA-G and the Interaction with Its Receptors: Where to Intervene for Cancer Immunotherapy? , 2020, International journal of molecular sciences.

[38]  E. Wolf,et al.  Older age groups and country-specific case fatality rates of COVID-19 in Europe, USA and Canada , 2020, Infection.

[39]  T. Aw,et al.  A Southeast Asian Perspective on the COVID-19 Pandemic: Hemoglobin E (HbE)-Trait Confers Resistance Against COVID-19 , 2020, Medical science monitor basic research.

[40]  A. Arnaiz-Villena,et al.  HLA‐G: Function, polymorphisms and pathology , 2020, International journal of immunogenetics.

[41]  S. Pääbo,et al.  The major genetic risk factor for severe COVID-19 is inherited from Neanderthals , 2020, Nature.

[42]  Barbara B. Shih,et al.  Genetic mechanisms of critical illness in COVID-19 , 2020, Nature.

[43]  Q. Shu,et al.  Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment , 2020, ESC heart failure.

[44]  S. Kang,et al.  From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses , 2020, Infection, Genetics and Evolution.

[45]  M. Gambardella,et al.  Heterogeneity of clinical and radiological findings of COVID-19 , 2020, Postgraduate Medical Journal.

[46]  S. Gregori,et al.  HLA-G Genotype/Expression/Disease Association Studies: Success, Hurdles, and Perspectives , 2020, Frontiers in Immunology.

[47]  Q. Ye,et al.  The mechanism and treatment of gastrointestinal symptoms in patients with COVID-19 , 2020, American journal of physiology. Gastrointestinal and liver physiology.

[48]  J. Vojtková,et al.  Immune Parameters and COVID-19 Infection – Associations With Clinical Severity and Disease Prognosis , 2020, Frontiers in Cellular and Infection Microbiology.

[49]  J. Erdmann,et al.  Genomewide Association Study of Severe Covid-19 with Respiratory Failure , 2020, The New England journal of medicine.

[50]  P. Kuppen,et al.  HLA-G: A New Immune Checkpoint in Cancer? , 2020, International journal of molecular sciences.

[51]  A. Basu,et al.  Faculty Opinions recommendation of Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. , 2020, Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature.

[52]  Q. Ye,et al.  Hepatic complications of COVID‐19 and its treatment , 2020, Journal of medical virology.

[53]  C. Pellegrini,et al.  NKG2A and COVID-19: another brick in the wall , 2020, Cellular & Molecular Immunology.

[54]  R. Bruno,et al.  Unique immunological profile in patients with COVID-19 , 2020, Cellular & Molecular Immunology.

[55]  Philippe P. Pébaÿ,et al.  COVID-19: beta-thalassemia subjects immunised? , 2020, Medical Hypotheses.

[56]  Q. Ye,et al.  The pathogenesis and treatment of the `Cytokine Storm' in COVID-19 , 2020, Journal of Infection.

[57]  Q. Shu,et al.  Epidemiological analysis of COVID‐19 and practical experience from China , 2020, Journal of medical virology.

[58]  E. Holmes,et al.  A new coronavirus associated with human respiratory disease in China , 2020, Nature.

[59]  Kai Zhao,et al.  A pneumonia outbreak associated with a new coronavirus of probable bat origin , 2020, Nature.

[60]  E. Holmes,et al.  Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding , 2020, The Lancet.

[61]  N. Messina,et al.  The impact of vaccines on heterologous adaptive immunity. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[62]  E. Donadi,et al.  Genetic association between HLA-G 14-bp polymorphism and diseases: A systematic review and meta-analysis. , 2018, Human immunology.

[63]  Edith Jasny,et al.  New Vaccine Technologies to Combat Outbreak Situations , 2018, Front. Immunol..

[64]  D. Hong,et al.  Meta-analysis of correlationship between HLA-G 3′UTR 14-bp Ins/Del polymorphism and virus susceptibility , 2018, Medicine.

[65]  T. Hviid,et al.  Next‐generation sequencing of HLA‐G based on long‐range polymerase chain reaction , 2018, HLA.

[66]  Jon Cohen Far from over. , 2018, Science.

[67]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[68]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[69]  E. Donadi,et al.  Haplotypes of the HLA-G 3’ Untranslated Region Respond to Endogenous Factors of HLA-G+ and HLA-G- Cell Lines Differentially , 2017, PloS one.

[70]  Lisa E. Gralinski,et al.  A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence , 2015, Nature Medicine.

[71]  A. Sabbagh,et al.  Insights into HLA-G Genetics Provided by Worldwide Haplotype Diversity , 2014, Front. Immunol..

[72]  U. d’Alessandro,et al.  The prevalence of glucose-6-phosphate dehydrogenase deficiency in Gambian school children , 2014, Malaria Journal.

[73]  S. Agaugué,et al.  Binding of HLA-G to ITIM-Bearing Ig-like Transcript 2 Receptor Suppresses B Cell Responses , 2014, The Journal of Immunology.

[74]  Eduardo A. Donadi,et al.  Polymorphic Sites at the 3’ Untranslated Region of the HLA-G Gene Are Associated with Differential hla-g Soluble Levels in the Brazilian and French Population , 2013, PloS one.

[75]  Christian Drosten,et al.  Commentary: Middle East Respiratory Syndrome Coronavirus (MERS-CoV): Announcement of the Coronavirus Study Group , 2013, Journal of Virology.

[76]  P. Marik,et al.  Narrative Review , 2012, Journal of intensive care medicine.

[77]  Jyothi Jayaraman,et al.  Copy number variation leads to considerable diversity for B but not A haplotypes of the human KIR genes encoding NK cell receptors , 2012, Genome research.

[78]  F. Weber,et al.  Extracellular 2′-5′ Oligoadenylate Synthetase Stimulates RNase L-Independent Antiviral Activity: a Novel Mechanism of Virus-Induced Innate Immunity , 2010, Journal of Virology.

[79]  E. Donadi,et al.  The genetic structure of 3′untranslated region of the HLA-G gene: polymorphisms and haplotypes , 2010, Genes and Immunity.

[80]  E. Capoluongo,et al.  Glucose‐6‐phosphate dehydrogenase laboratory assay: How, when, and why? , 2009, IUBMB life.

[81]  C. Vilches,et al.  Facilitation of KIR genotyping by a PCR-SSP method that amplifies short DNA fragments. , 2007, Tissue antigens.

[82]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[83]  O. Christiansen,et al.  HLA-G and IL-10 in serum in relation to HLA-G genotype and polymorphisms , 2004, Immunogenetics.

[84]  A. Cariou,et al.  Coronavirus 229E-Related Pneumonia in Immunocompromised Patients , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  J. R. Lapa e Silva,et al.  Another brick in the wall. , 2002, Sao Paulo medical journal = Revista paulista de medicina.

[86]  J. Dausset,et al.  An alternatively spliced form of HLA-G mRNA in human trophoblasts and evidence for the presence of HLA-G transcript in adult lymphocytes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[87]  D. Geraghty,et al.  Alternative splicing of HLA-G transcripts yields proteins with primary structures resembling both class I and class II antigens. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[88]  Y. Azuma,et al.  [Long-term results of short course chemotherapy of pulmonary tuberculosis. Second study-B: results at 6 years after the end of 4-9 month chemotherapy of pulmonary tuberculosis]. , 1987, Kekkaku : [Tuberculosis].

[89]  A. Cao,et al.  Beta thalassaemia mutations in Sardinians: implications for prenatal diagnosis. , 1987, Journal of medical genetics.

[90]  W. Kruskal,et al.  Use of Ranks in One-Criterion Variance Analysis , 1952 .

[91]  F. Meloni,et al.  Natural killer-cell immunoglobulin-like receptors trigger differences in immune response to SARS-CoV-2 infection , 2021, PloS one.

[92]  E. Gianicolo,et al.  [Sex/gender differences in COVID-19 lethality: what the data say, and do not say]. , 2020, Epidemiologia & Prevenzione.

[93]  J. Sterne,et al.  Essential Medical Statistics , 2003 .

[94]  R. B. Heisch How, what and why. , 1963, East African medical journal.